Effect of Media Modified To Mimic Cystic Fibrosis Sputum on the Susceptibility of Aspergillus fumigatus, and the Frequency of Resistance at One Center

Antimicrobial Agents and Chemotherapy
David A StevensMarife Martinez

Abstract

Studies of cystic fibrosis (CF) patient exacerbations attributed toPseudomonas aeruginosainfection have indicated a lack of correlation of outcome within vitrosusceptibility results. One explanation is that the media used for testing do not mimic the airway milieu, resulting in incorrect conclusions. Therefore, media have been devised to mimic CF sputum.Aspergillus fumigatusis the leading fungal pathogen in CF, and susceptibility testing is also used to decide therapeutic choices. We assessed whether media designed to mimic CF sputa would give different fungal susceptibility results than those of classical methods, assaying voriconazole, the most utilized anti-Aspergillusdrug in this setting, and 30 CFAspergillusisolates. The frequency of marked resistance (defined as an MIC of >4 μg/ml) in our CF unit by classical methods is 7%. Studies performed with classical methods and with digested sputum medium, synthetic sputum medium, and artificial sputum medium revealed prominent differences inAspergillussusceptibility results, as well as growth rate, with each medium. Clinical correlative studies are required to determine which results are most useful in predicting outcome. Comparison of MICs with non-CF isolates also indicated the ...Continue Reading

References

Feb 1, 1997·Zentralblatt Für Bakteriologie : International Journal of Medical Microbiology·P M RathR Ansorg
Nov 22, 1997·Diagnostic Microbiology and Infectious Disease·D A Stevens, B H Aristizabal
Dec 24, 1997·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C NeuvégliseJ P Latgé
Sep 13, 2003·American Journal of Respiratory and Critical Care Medicine·Claudia L OrdoñezMoira L Aitken
Sep 17, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David A StevensUNKNOWN Participants in the Cystic Fibrosis Foundation Consensus Conference
Jun 11, 2005·Journal of Medical Microbiology·Dinesh D SriramuluUte Römling
Jul 15, 2006·Chest·David ShoseyovEitan Kerem
Sep 18, 2007·Journal of Bacteriology·Kelli L PalmerMarvin Whiteley
Jan 8, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas J WalshUNKNOWN Infectious Diseases Society of America
May 7, 2008·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·L M E VanheeT Coenye
Dec 2, 2008·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Hanneke A de ValkJacques F G M Meis
Jul 25, 2009·Emerging Infectious Diseases·Susan J HowardDavid W Denning
Nov 3, 2009·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Paul E VerweijDavid W Denning
Nov 21, 2009·The Lancet Infectious Diseases·Paul E VerweijWillem J G Melchers
Aug 28, 2010·Medical Mycology·Susan Julie Howard, Maiken Cavling Arendrup
Feb 1, 2011·Journal of Microbiological Methods·Caroline G BaxterDavid W Denning
Apr 7, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David W DenningDavid S Perlin
Nov 30, 2011·Antimicrobial Agents and Chemotherapy·Pierre-Régis BurgelAndré Paugam
Mar 23, 2012·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·M N HurleyA R Smyth
Jul 14, 2012·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·D J SerisierG Jones
Jul 27, 2012·Scandinavian Journal of Infectious Diseases·Judith FillauxJean-François Magnaval
Aug 21, 2012·American Journal of Respiratory and Critical Care Medicine·Catherine A CoughlanNoel G McElvaney
Sep 12, 2012·Current Opinion in Pulmonary Medicine·Jennifer J SpeirsJeffrey M Beekman
Jan 29, 2013·Applied and Environmental Microbiology·Volker BehrendsJacob G Bundy
Sep 26, 2013·Current Opinion in Pulmonary Medicine·Peter G MiddletonWieland Meyer
Oct 17, 2014·American Journal of Respiratory and Critical Care Medicine·Kathryn A RamseyUNKNOWN AREST CF
Dec 3, 2014·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Raquel SabinoDavid A Stevens
Mar 17, 2015·Proceedings of the National Academy of Sciences of the United States of America·Keith H TurnerMarvin Whiteley
Apr 22, 2015·Antimicrobial Agents and Chemotherapy·Musang LiuWeida Liu

❮ Previous
Next ❯

Citations

Apr 20, 2017·Mycopathologia·Raquel SabinoDavid A Stevens
Dec 7, 2016·BMC Pulmonary Medicine·Anjali Y BhagirathKangmin Duan
Dec 15, 2020·ERJ Open Research·Tobias EngelEveline Snelders
Jul 29, 2021·Mycopathologia·C SchwarzJ P Bouchara
Aug 29, 2021·Pathogens·Sebastián A Riquelme, Alice Prince

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Related Papers

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Larissa LaineF Kate Gould
The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases
L R R Perez, A L Barth
© 2021 Meta ULC. All rights reserved